Accessibility Menu
 
Innate Pharma logo

Innate Pharma

(NASDAQ) IPHA

Current Price$1.38
Market Cap$141.79M
Since IPO (2019)-75%
5 Year-65%
1 Year-42%
1 Month+1%

Innate Pharma Financials at a Glance

Market Cap

$141.79M

Revenue (TTM)

$15.41M

Net Income (TTM)

$98.44M

EPS (TTM)

$-0.61

P/E Ratio

-2.46

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$1.38

Volume

485

Open

$1.45

Previous Close

$1.38

Daily Range

$1.38 - $1.45

52-Week Range

$1.17 - $2.63

IPHA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innate Pharma

Industry

Biotechnology

Employees

163

CEO

Jonathan Dickinson, MBA

Headquarters

Marseille, 13009, FR

IPHA Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-21%

Net Income Margin

-18%

Return on Equity

-271%

Return on Capital

-2%

Return on Assets

-78%

Earnings Yield

-40.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$141.79M

Shares Outstanding

93.90M

Volume

485

Avg. Volume

24.85K

Financials (TTM)

Gross Profit

$2.79M

Operating Income

$53.42M

EBITDA

$43.65M

Operating Cash Flow

$50.67M

Capital Expenditure

$134.47K

Free Cash Flow

$50.81M

Cash & ST Invst.

$34.30M

Total Debt

$22.56M

Innate Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.07M

-112.5%

Gross Profit

$18.45M

+690.1%

Gross Margin

-8.90%

N/A

Market Cap

$141.79M

N/A

Market Cap/Employee

$783.39K

N/A

Employees

181

N/A

Net Income

$27.63M

-197.4%

EBITDA

$30.71M

-195.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$11.73M

-77.7%

Accounts Receivable

$12.39M

-73.3%

Inventory

$0.00

N/A

Long Term Debt

$13.77M

-55.5%

Short Term Debt

$8.80M

-1.5%

Return on Assets

-78.41%

N/A

Return on Invested Capital

-2.20%

N/A

Free Cash Flow

$23.48M

-11.1%

Operating Cash Flow

$23.40M

-10.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRBPCorbus Pharmaceuticals Holdings, Inc.
$10.87-0.46%
MOLNMolecular Partners AG
$4.10-4.33%
MISTMilestone Pharmaceuticals Inc.
$1.89-4.06%
CRDFCardiff Oncology, Inc.
$1.60-4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$12.35-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.47+0.07%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.34-0.00%
SNAPSnap
$5.98-0.02%

Questions About IPHA

What is the current price of Innate Pharma?

Innate Pharma is trading at $1.38 per share.

What is the 52-week range for Innate Pharma?

Over the past 52 weeks, Innate Pharma has traded between $1.17 and $2.63.

How much debt does Innate Pharma have?

As of the most recent reporting period, Innate Pharma reported total debt of $26.51M.

How much cash does Innate Pharma have on hand?

Innate Pharma reported $32.99M in cash and cash equivalents in its most recent financial results.

What is Innate Pharma’s dividend yield?

Innate Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.